SK Biopharmaceuticals Co Ltd
KRX:326030
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
SK Biopharmaceuticals Co Ltd
Balance Sheet
Balance Sheet Decomposition
SK Biopharmaceuticals Co Ltd
| Current Assets | 551.5B |
| Cash & Short-Term Investments | 267.5B |
| Receivables | 141.7B |
| Other Current Assets | 142.3B |
| Non-Current Assets | 223.5B |
| Long-Term Investments | 85.8B |
| PP&E | 41B |
| Intangibles | 34B |
| Other Non-Current Assets | 62.7B |
| Current Liabilities | 338.5B |
| Accounts Payable | 3.8B |
| Accrued Liabilities | 63.2B |
| Short-Term Debt | 50B |
| Other Current Liabilities | 221.5B |
| Non-Current Liabilities | 98.6B |
| Long-Term Debt | 24.4B |
| Other Non-Current Liabilities | 74.2B |
Balance Sheet
SK Biopharmaceuticals Co Ltd
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
25 272
|
74 292
|
51 141
|
59 333
|
225 922
|
104 060
|
239 700
|
|
| Cash Equivalents |
25 272
|
74 292
|
51 141
|
59 333
|
225 922
|
104 060
|
239 700
|
|
| Short-Term Investments |
39 079
|
2 236
|
31 234
|
328 657
|
108 417
|
201 394
|
1 418
|
|
| Total Receivables |
15 388
|
1 531
|
2 546
|
12 638
|
61 675
|
67 021
|
115 847
|
|
| Accounts Receivables |
14 612
|
118
|
1 379
|
9 992
|
56 460
|
66 326
|
111 422
|
|
| Other Receivables |
776
|
1 413
|
1 167
|
2 646
|
5 214
|
694
|
4 425
|
|
| Inventory |
865
|
162
|
6 733
|
23 040
|
51 933
|
90 920
|
102 525
|
|
| Other Current Assets |
1 225
|
3 336
|
7 027
|
10 935
|
23 272
|
24 530
|
29 232
|
|
| Total Current Assets |
81 828
|
81 558
|
98 681
|
434 603
|
471 219
|
487 925
|
488 722
|
|
| PP&E Net |
13 822
|
12 154
|
25 897
|
24 233
|
22 938
|
20 350
|
47 753
|
|
| PP&E Gross |
0
|
12 154
|
25 897
|
24 233
|
22 938
|
20 350
|
47 753
|
|
| Accumulated Depreciation |
0
|
19 691
|
22 825
|
30 356
|
37 056
|
45 101
|
54 599
|
|
| Intangible Assets |
246
|
246
|
883
|
19 695
|
18 900
|
17 181
|
23 633
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
3 392
|
|
| Note Receivable |
36
|
41
|
41
|
0
|
27
|
79
|
85
|
|
| Long-Term Investments |
459
|
7
|
7
|
6 849
|
107 665
|
99 959
|
104 091
|
|
| Other Long-Term Assets |
1 976
|
1 530
|
13 564
|
14 862
|
22 904
|
38 748
|
55 494
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
3 392
|
|
| Total Assets |
98 367
N/A
|
95 536
-3%
|
139 073
+46%
|
500 241
+260%
|
643 652
+29%
|
664 241
+3%
|
723 171
+9%
|
|
| Liabilities | ||||||||
| Accounts Payable |
23 828
|
0
|
0
|
8 954
|
16 931
|
23 106
|
2 346
|
|
| Accrued Liabilities |
16 273
|
24 034
|
35 103
|
36 543
|
64 776
|
55 035
|
71 331
|
|
| Short-Term Debt |
0
|
0
|
100 000
|
0
|
0
|
0
|
50 000
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
3 197
|
4 906
|
5 481
|
5 644
|
7 061
|
|
| Other Current Liabilities |
6 878
|
6 936
|
7 341
|
20 193
|
61 117
|
79 287
|
110 881
|
|
| Total Current Liabilities |
46 978
|
30 970
|
145 641
|
70 595
|
148 306
|
163 073
|
241 619
|
|
| Long-Term Debt |
0
|
0
|
5 858
|
13 572
|
10 256
|
150 252
|
120 989
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1 909
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
37 265
|
|
| Other Liabilities |
4 146
|
5 936
|
599
|
37 007
|
40 903
|
34 356
|
37 703
|
|
| Total Liabilities |
51 125
N/A
|
36 906
-28%
|
152 098
+312%
|
121 175
-20%
|
199 465
+65%
|
347 681
+74%
|
439 484
+26%
|
|
| Equity | ||||||||
| Common Stock |
25 000
|
32 500
|
32 500
|
39 157
|
39 157
|
39 157
|
39 157
|
|
| Retained Earnings |
286 862
|
426 403
|
498 948
|
746 951
|
689 141
|
827 555
|
861 561
|
|
| Additional Paid In Capital |
303 579
|
446 040
|
446 040
|
1 084 848
|
1 084 848
|
1 084 848
|
1 084 848
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
268
|
11 816
|
13 242
|
|
| Other Equity |
5 525
|
6 493
|
7 383
|
2 013
|
9 056
|
8 296
|
8 001
|
|
| Total Equity |
47 243
N/A
|
58 629
+24%
|
13 025
N/A
|
379 067
N/A
|
444 187
+17%
|
316 560
-29%
|
283 686
-10%
|
|
| Total Liabilities & Equity |
98 367
N/A
|
95 536
-3%
|
139 073
+46%
|
500 241
+260%
|
643 652
+29%
|
664 241
+3%
|
723 171
+9%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
50
|
65
|
65
|
78
|
78
|
78
|
78
|
|
You don't have any saved screeners yet
